• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Aspirin use was not effective at reducing mortality in patients hospitalized with COVID-19

byNeel MistryandTeddy Guo
January 25, 2022
in Cardiology, Hematology, Infectious Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. There was no significant difference in all-cause mortality and need for invasive mechanical ventilation among patients assigned to aspirin versus usual care group.

2. Although aspirin was associated with a reduction in rate of thrombotic events, there were also increases in major bleeding.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients hospitalized with COVID-19 often encounter thromboembolic events during their stay. Although current guidelines suggest use of low molecular weight heparin (LMWH), more affordable and accessible drugs should be explored. Aspirin, a cyclooxygenase-1 enzyme (COX-1) inhibitor, is known to reduce both arterial and venous thrombotic events although its use in patients with COVID-19 lacks evidence. This randomized control trial aimed to assess the safety and efficacy of aspirin among patients admitted with COVID-19. Individuals were assigned to either standard of care plus aspirin (intervention group) or standard of care alone (control group). The primary outcome was mortality at 28 days, while key secondary outcomes included length of hospital stay and need for mechanical ventilation. According to study results, all-cause mortality was similar in both groups, although individuals in the intervention group experienced a shorter hospital stay. A notable limitation of this study was that patients already using aspirin, likely due to increased cardiovascular risk factors, were excluded from study enrollment. Nonetheless, this randomized controlled trial provides crucial information regarding the efficacy of aspirin for a large sample of patients with COVID-19.

Click to read the study in The Lancet

Relevant Reading: Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease

In-depth [randomized controlled trial]: Between Nov 1, 2020, and Mar 21, 2021, 22 560 patients were assessed for eligibility across 177 hospitals in the UK, Indonesia, and Nepal. Included were those ≥18 years with suspected or confirmed COVID-19, and no contraindications to aspirin or otherwise. Altogether, 14 892 patients were included (7351 to aspirin and 7541 to usual care group) in the final analysis. The primary outcome of all-cause mortality was unchanged with an equal proportion (17%) of patients dying in each group (1222 of 7351 with aspirin vs. 1299 of 7541 with usual care, rate ratio [RR] 0.96, 95% confidence interval [CI] 0.89-1.04, p=0.35). Likewise, there was marginal difference between groups regarding patients who required invasive mechanical ventilation (21% with aspirin vs. 22% with usual care, RR 0.96, 95% CI 0.90-1.03, p=0.23). However, aspirin was associated with decreased length of admission (8 days vs. 9 days) and increased likelihood of hospital discharge within 28 days (75% vs. 74%, p=0.0062) compared to usual care. Overall, aspirin did not show a significant difference in all-cause mortality among COVID-19 patients and its use in addition to routine thromboprophylaxis may be discouraged.

RELATED REPORTS

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

Active surveillance strategies to improve rates of inferior vena cava filter retrieval

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anticoagulationantiplateletaspirinCOVID-19SARS-CoV-2thromboembolismthrombosisvenous thromboembolism
Previous Post

Balanced-multi-electrolyte-solution does not reduce risk of death among intensive care patients

Next Post

Premorbid neurodegenerative disease associated with increased risk of COVID-19 infection and death

RelatedReports

Endocrinology

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

March 24, 2023
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Cardiology

Active surveillance strategies to improve rates of inferior vena cava filter retrieval

March 22, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

March 21, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Public Health

Prior COVID-19 infection may result in poorer sleep health

March 17, 2023
Next Post

Premorbid neurodegenerative disease associated with increased risk of COVID-19 infection and death

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

#VisualAbstract: Rivaroxaban prophylaxis improves clinical outcomes in high-risk patients hospitalized with COVID-19

Novel coronavirus identified from patients with pneumonia in Wuhan, China

mRNA Covid-19 vaccine remained safe and efficacious through 6 months

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
  • Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options